Matritech Announces $12.55 Million Financing

Matritech, a developer of proteomics-based diagnostic products, has entered into an agreement providing for a $12.55 million private placement for the sale of 1,426,124 shares of its Series A Convertible Preferred Stock, each share of which is convertible into 10 shares of common stock, and five-year warrants to purchase 4,991,382 shares of common stock at an exercise price of $1.47 per share.

Boston dBusinessNews (http://boston.dbusinessnews.com/shownews.php?newsid=13248&type_news=latest)